

## PROGRAM REGISTRATION

Please complete form on reverse  
and submit by mail or fax, or call  
1-888-Doc-Opt-In (1-888-362-6784)  
or via the Internet at [www.docoptin.com](http://www.docoptin.com)

BUPRENORPHINE AND  
Office-Based Treatment  
Of OPIOID  
DEPENDENCE



American  
Osteopathic  
Academy of  
Addiction  
Medicine



## BUPRENORPHINE AND Office-Based Treatment of OPIOID DEPENDENCE

FRIDAY, AUGUST 12, 2005

7:30 a.m. - 5:00 p.m.

**Location: Seattle Tacoma, WA**

**La Quinta Inn & Suites**

1425 E. 27th St.

Tacoma, WA 98421-2200

Phone: (253) 383-0146

This program is part of a national training initiative, which has been endorsed by the Federal Center for Substance Abuse Treatment (CSAT) and is sponsored by the American Osteopathic Academy of Addiction Medicine. Physicians who complete this course will be eligible to request a waiver to practice medical-assisted addiction therapy with Buprenorphine, for the treatment of opioid dependence.

[www.samhsa.gov](http://www.samhsa.gov)    [www.buprenorphine.samhsa.gov](http://www.buprenorphine.samhsa.gov)

## PROGRAM GOALS

After attending this session participants will be able to:

- Describe prerequisites for a physician to begin to prescribe buprenorphine in office-based practice
- Discuss clinically relevant pharmacological characteristics of buprenorphine
- Identify factors to consider in determining if a patient is an appropriate candidate for office-based treatment
- Describe induction and maintenance protocols
- Discuss strategies for integrating psychosocial care with office-based pharmacological treatment
- Discuss treatment strategies for management of chronic and acute pain in patients in maintenance treatment for opioid dependence

To fully complete the form necessary to prescribe Buprenorphine, please bring your DEA number and your group practice or solo practice Tax ID employer identification number as well as the names and DEA numbers of other physicians in your practice who will be prescribing Buprenorphine for opioid addiction.

## PROGRAM OVERVIEW

The Drug Addiction Treatment Act of 2000 permits physicians who are trained or experienced in opioid addiction treatment to obtain waivers to prescribe certain narcotic drugs in Schedule III, IV or V of the Controlled Substances Act, in their office practices or in a clinic setting, for the treatment of opioid dependence. Both buprenorphine and the combination of buprenorphine with naloxone are approved by the FDA for use in detoxification and maintenance treatment of opioid dependence.

As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. Physicians who complete this course will meet the training qualification under the new law and will receive a certificate of attendance suitable to send to the Secretary of HHS along with the request for the waiver. If you give AOAAM permission to do so, AOAAM will report your name directly to the Secretary of HHS within 4 weeks of the program thus eliminating the need for you to send the certificate of attendance.

### WHO SHOULD ATTEND

This program is recommended for primary care, pain management, psychiatric, HIV and addiction medicine physicians. Other professionals (non-physicians) are also invited but will not be able to be eligible for the waiver.

### CONTINUING MEDICAL EDUCATION

This program anticipates being approved for 8.0 AOA Category 1-A CME credit hours pending approval by the AOA CCME. It is also approved for 8.0 AAFP Prescribed Credit hours which are eligible for the AMA's Physician Recognition Award Credit.

### SPONSORSHIP

- Sponsored by the American Osteopathic Academy of Addiction Medicine (AOAAM)
- Sponsored by the Clinical Support Center of the Indian Health Service
- Supported by the Centers for Substance Abuse Treatment and
- Supported by an unrestricted medical education grant provided by Reckitt Benckiser.

## PROGRAM REGISTRATION

YOU MAY REGISTER BY VISITING OUR WEBSITE AT [WWW.DOCOPTIN.COM](http://WWW.DOCOPTIN.COM); OR BY CALLING 1-888-DOC-OPT-IN (888-362-6784). OR COMPLETE THE FORM BELOW AND SUBMIT BY MAIL OR FAX.

FULL NAME: \_\_\_\_\_

\_\_\_ I AM A PHYSICIAN \_\_\_ DO \_\_\_ MD

ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_

PHONE ( ) \_\_\_\_\_ FAX ( ) \_\_\_\_\_

E-MAIL \_\_\_\_\_

Registration Fee: \$100 (includes lunch). No fee for residents, hospital faculty, IHS members, and federal, state and municipal physicians and staff.

\* Preregistration is recommended, as space is limited and registrations are accepted on a first come, first serve basis.

**Cancellation Policy:** The deadline to cancel with a refund is within 14 calendar days of the meeting.

PLEASE COMPLETE THIS FORM AND SUBMIT BY MAIL OR FAX.

Make all checks payable to: **AOAAM**

Mail: Nina Albano Vidmer & Associates

3800 Division St., Stone Park, IL 60165

Phone: 708-338-0760

Fax: 708-338-0997

Charge to my \_\_\_ Visa or \_\_\_ Master Card (check one)

Card # \_\_\_\_\_

Expiration Date: \_\_\_\_\_

Signature: \_\_\_\_\_

**IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT NINA ALBANO VIDMER @ [NVIDMER@AOAAM.ORG](mailto:NVIDMER@AOAAM.ORG)**

To fully complete the form necessary to prescribe Buprenorphine, please bring your DEA number and your group practice employer identification number (Tax ID Number), as well as the names and DEA numbers of other physicians in your practice who will be prescribing Buprenorphine for opioid addiction.

## PROGRAM FACULTY

### *COURSE DIRECTOR:*

**Anthony Dekker, DO, FAOAAM**  
Associate Director, Ambulatory Care and  
Community Health  
Phoenix Indian Medical Center

### *SPEAKERS:*

**Laura McNicholas, MD, PhD**  
Director of Addiction Medicine  
Philadelphia VAMC  
Clinical Professor University of Penn.

For Registration or information, visit  
**[www.docoptin.com](http://www.docoptin.com)**  
or call 1-888-Doc-Opt-In  
(1-888-362-6784)

## TOPICS TO BE DISCUSSED

Registration & Pre-course Questionnaire

INTRODUCTION – Course Description  
The New Law: DATA 2000

Basic Opioid and Buprenorphine Pharmacology

Medical Co-Morbidities

Psych – Co-Morbidities

Patient Selection, Assessment

Questions and Answers - Panel

BREAK/ BOX LUNCH- How to fill out the Waiver –  
FOLLOWED BY MANDATORY SIGN IN

Treatment of Pain in Patients with an Addiction

Special Populations

Clinical Management of Buprenorphine  
*Policies and Procedures, Confidentiality and  
Medical Record Keeping with Buprenorphine*

Questions and Answers - Panel

Case Presentation and clinical vignettes-Panel

Post Course Assessment & Questionnaire

MANDATORY SIGN OUT


## DIRECTIONS

### La Quinta Inn & Suites Seattle Tacoma

1425 E. 27th St.

Tacoma, WA 98421-2200

Phone: (253) 383-0146



## DIRECTIONS

I-5 S-bound: exit 135-Portland Ave. I-5 N-bound: exit 134-Portland Ave., turn left